BioPharma Resources

Drug Trial Radar · NCT05214482

A Study of AK112 in Advanced Malignant Tumors

A Phase Ib/II Study of AK112(PD-1 / VEGF Bispecific Antibody) in Combination With AK117(Anti-CD47 Antibody)With or Without Chemotherapy in Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

154

Actual

Start

Jan 22, 2022

Primary completion

Nov 20, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Jan 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117(Anti-CD47 Antibody)with or without chemotherapy in advanced malignant tumors

Conditions

  • Advanced Malignant Tumors

Interventions

  • AK112Drug

    IV infusion,Specified dose on specified days

  • AK117Drug

    IV infusion,Specified dose on specified days

  • ChemotherapyDrug

    IV infusion,Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with Adverse Events (AEs)Time frame: Up to approximately 2 years
  2. Objective Response Rate (ORR)Time frame: Up to approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.